iCAC Device vs ElucidVivo A.3
AI Verdict
Choose iCAC Device if…
Choose the iCAC Device if your primary objective is opportunistic screening for early cardiovascular disease risk in a broad patient population. This tool is ideal for leveraging existing, routine non-contrast chest CT scans to quickly identify and quantify coronary artery calcium, providing adjunctive information for early risk stratification without requiring dedicated cardiac imaging.
View iCAC Device →Choose ElucidVivo A.3 if…
Choose ElucidVivo A.3 if you require in-depth, quantitative analysis of arterial plaque composition and stability for patients with known or suspected atherosclerosis. This tool is best suited for optimizing treatment decisions and stratifying patient risk by providing detailed visualization and measurement of plaque characteristics from CT angiography, including lipid-rich necrotic core and calcifications, validated against histology.
View ElucidVivo A.3 →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | iCAC Device | ElucidVivo A.3 |
|---|---|---|
| Pricing | Contact for pricing | Unknown |
| Deployment | Software as a Medical Device (SaMD), integrates with PACS or DICOM router. Cloud-based (via Carebricks platform). | Cloud and on-premise secure deployment. |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
iCAC DeviceTool A, iCAC Device, prioritizes seamless integration into existing radiology workflows by leveraging routine, non-contrast, non-gated chest CT scans, eliminating the need for specialized imaging protocols. Its integration with the Carebricks platform further automates patient identification, risk stratification, and care coordination, significantly reducing manual clinician workload and enhancing overall workflow efficiency for opportunistic screening.
Clinical Value
ElucidVivo A.3Tool B, ElucidVivo A.3, offers superior clinical value through its advanced quantitative analysis of arterial plaque composition and stability, including Lipid-Rich Necrotic Core (LRNC) and derived Fractional Flow Reserve (FFRct), from CT angiography. This detailed characterization is uniquely validated against ground-truth histology, providing deeper, more actionable insights for precise atherosclerosis patient stratification and optimized treatment decisions.
Pricing & Value
iCAC DeviceWhile both tools require direct vendor contact for pricing, Tool A, iCAC Device, has secured a clear reimbursement pathway with CMS establishing a national billing code (G0680) and an associated payment rate of $15.50 for algorithmic analysis of coronary artery calcium (CAC) and aortic valve calcium (AVC). This explicit per-scan reimbursement provides a more immediately quantifiable financial value proposition for health systems implementing opportunistic screening programs.
Enterprise Readiness
iCAC DeviceTool A, iCAC Device, demonstrates stronger enterprise readiness through its explicit classification as Software as a Medical Device (SaMD) and its deployment via the cloud-based Carebricks platform, which is designed for end-to-end care navigation and automation across various clinical and operational workflows. Bunkerhill Health also clearly states compliance with HIPAA, SOC 2, and ISO 27001:2022 standards on its Trust Center, indicating robust security and data governance.
Innovation
ElucidVivo A.3Tool B, ElucidVivo A.3, exhibits greater innovation by providing a unique, histologically validated quantitative analysis of arterial plaque composition and stability, including LRNC and FFRct, from CT angiography. This capability offers novel predictive insights for personalized atherosclerosis management, effectively delivering 'CT Virtual Histology' and moving beyond traditional diagnostic assistance.
Support & Docs
TieNeither the provided structured facts nor the extensive web search results offer sufficient specific information regarding the quality, availability, or scope of support and documentation for either the iCAC Device or ElucidVivo A.3. Therefore, it is not possible to distinguish between the two tools on this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | iCAC Device | ElucidVivo A.3 |
|---|---|---|
| Name | iCAC Device | ElucidVivo A.3 |
| Company | Bunkerhill Health | Elucid Bioimaging |
| Primary Purpose | Detects and quantifies coronary artery calcium from routine, non-contrast, non-gated chest CT scans, aiding in early cardiovascular disease detection. | Provides quantitative analysis of arterial plaque composition and stability from CT angiography, assisting physicians in atherosclerosis patient stratification and optimizing treatment decisions. |
| Input Scan Type | Routine, non-contrast, non-gated chest CT scans | CT angiography |
| Key Output Metrics/Analysis | Estimates presence and quantity of coronary artery calcium (CAC), provides visual representation of estimated CAC segmentation, delivers exact and four-category quantitative estimates of CAC burden in Agatston units. | AI-powered quantitative analysis of arterial plaque, objectively quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications, visualizes lesion-level plaque composition, provides 3D visualization of highlighted vessels, offers rotatable curved MPR vessel views and cross-sections, derives fractional flow reserve (FFRct). |
| Integration | Integrates with PACS or DICOM router, integrates with EHRs via the Carebricks platform. | Integrates with PACS/EMR (not explicitly detailed). |
| Specialties | Cardiology, Radiology | Cardiology, Radiology, Vascular Surgery |
Videos
Demos, reviews, and walkthroughs featuring iCAC Device and ElucidVivo A.3.